Cochrane · systematic review · CD004720
Screening for prostate cancer
Ilic, D, Neuberger, MM, Djulbegovic, M, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 3 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Screening for prostate cancer
Population: adult male patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes1 | no estimate extracted | NR | No studies |
All‐cause mortality | RR 1 [0.96, 1.03] | 4 studies · 294856 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Prostate cancer‐specific mortality | RR 1 [0.86, 1.17] | 5 studies · 341342 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Prostate cancer diagnosis | RR 1.3 [1.02, 1.65] | 4 studies · 294856 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Tumour stage (localised T1‐T2, N0, M0) | RR 1.79 [1.19, 2.7] | 3 studies · 247954 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Tumour stage (advanced T3‐4, N1, M1) | RR 0.8 [0.73, 0.87] | 3 studies · 247954 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |